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Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers
studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a
favourable prognosis. However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect
of the expression of different combinations of these receptors on patient survival is not well understood. Therefore, we examined
the mRNA expression of all four EGF receptors with real-time polymerase chain reaction in biopsies from 88 patients with bladder
cancer, where the survival was followed for a median of 38.5 months (range 1–117 months). Expression of HER1 and HER2 alone
showed no correlation with survival. However, a high expression of HER1 together with high expression of HER3 and HER4
correlated to a better prognosis compared to the high expression of HER1 together with low expression of HER3 and HER4
(P¼0.0006). Also, a significantly longer survival was observed in patients expressing high HER2 when coexpressed with high HER3
and HER4, as compared to the survival in patients with tumours expressing high HER2 but low HER3 and HER4 (P¼0.0005). Our
results suggest that the final outcome of patients with high HER1- and HER2-expressing tumours depends on the expression of HER3
and HER4.
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The epidermal growth factor (EGF) family of receptor tyrosine
kinases comprises four members: HER1 (EGF receptor 1 Human
EGF Receptor/ErbB1), HER2 (neu/ErbB2), HER3 (ErbB3) and
HER4 (ErbB4) (Yarden and Sliwkowski, 2001). Epidermal growth
factor receptors are commonly active in a dimeric form and
interaction between different EGF receptor pairs represents a
mechanism for signal diversification and amplification (Olayioye
et al, 2000; Yarden and Sliwkowski, 2001). Various dimeric pairs
depend on the concentration of receptors, the concentration of
particular ligands and the affinity of the receptors towards each
other (Pinkas-Kramarski et al, 1996; Tzahar et al, 1997). Ligands
binding the EGF family receptors induce receptor homo- or
heterodimerisation, which involves an array of a number of
homodimeric and heterodimeric combinations (Burden and
Yarden, 1997). The ligands for these receptors consist of
approximately 20 different proteins (including isoforms) encoded
by at least 10 different genes. The numerous EGF family-specific
ligands include EGF and five other ligands able to bind to HER1.
Whereas heregulins are the ligands for HER3 and HER4. No ligand
for HER2 has been identified and HER3 lacks intrinsic tyrosine
kinase activity (Guy et al, 1994). Thus, the normal mechanism by
which HER2 or HER3 can signal is through heterodimerisation
with other EGF receptors.
Epidermal growth factor receptors, particularly HER1 and
HER2, are commonly deregulated in certain forms of human
cancer including bladder cancer. It has been shown that HER1 and
HER2 expressions are involved in poor prognosis (Garcia et al,
2003; Nielsen et al, 2004; Tovey et al, 2004). Despite the numerous
studies devoted to the issue of clinical significance of HER1 and
HER2, the role of these receptors is still controversial in bladder
cancer.
The role of the HER3 and HER4 receptors is not well
understood. However, growing consensus has emerged about the
role of HER4, and the few clinical studies carried out so far have
suggested that its expression is associated with favourable
prognosis (Thybusch-Bernhardt et al, 2001; Suo et al, 2002;
Rotterud et al, 2005). We have shown that HER3 and HER4
expression correlated with a better prognosis in bladder cancer
patients (Memon et al, 2004). More recent reports also suggest that
unlike HER1 and HER2, expression of HER3 and HER4 was not
found in more aggressive metastatic squamous cell carcinomas of
the oral cavity (Ekberg et al, 2005). The same was reported in
meningiomas (Andersson et al, 2004). In addition, presence of
HER4 in HER2-expressing tumours reduced the recurrence in
breast cancer patients, further supporting the distinct roles for
EGF family receptors (Barnes et al, 2005).
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more potent in signal transduction than homodimers. Hetero-
dimers provide additional phosphotyrosine residues for the
recruitment of effector proteins, and induce distinct patterns of
receptor phosphrylation and downstream signalling. This suggests
that the outcome of activation of the EGF system depends on the
interaction between the EGF receptors.
The prognostic significance of all four receptors in different
combinations remains unclear. Knowledge about this is important
in order to design the best cancer treatment directed towards these
receptors. Today, drugs directed towards HER1 (e.g. iressa/
gefitinib) and HER2 (e.g. trastuzumab) (Diermeier et al, 2005)
are already in clinical use and strategies involving inhibition of all
four receptors are under evaluation. Therefore, it is important that
all four EGF receptors should be analysed in the same group of
patients before drawing any conclusion about the prognostic
significance of these receptors. Lack to do so could be one of the
reasons for the conflicting data about the role of HER1 and HER2
as prognostic markers.
Epidermal growth factor family gene expression can reliably be
studied at the mRNA level and based on a number of studies, the
expression is likely to reflect the presence of the corresponding
protein (Knowlden et al, 1998; Walker and Dearing, 1999; Suo et al,
2002; Junttila et al, 2003).
The present study was undertaken in order to examine the
pattern of expression of HER1-4 in bladder cancer biopsies from
88 patients in relation to survival of the patients. We report that a
high expression of HER3 and/or HER4 protects the patients from
the consequences of a high expression of HER1 and/or HER2.
MATERIALS AND METHODS
Patients
Eighty-eight patients with primary bladder cancer were included.
Biopsies were obtained by transurethral tumour resection and
alliqotes were frozen immediately. Samples for histological
examination were removed before freezing and analysed indepen-
dent of the further analysis of RNA. Tumour stage was assigned
according to the Union Internationale Contre le Cancer Tumour-
Node-Metastasis system (Spiessl et al, 2003). Grading was
performed in accordance with methods described by Bergkvist
et al (1965). The relationship between the distribution of tumour
stage, age and sex is summarised in Table 1. At the time of
inclusion, 18 patients had received treatment in the form of radical
radiotherapy, chemotherapy or intravesical therapy with bacillus
Calmette-Guerin. The follow-up period was from the date of
biopsy to the day of death or to July 2005. Patients were censored if
they were alive at the time of analysis (July 2005). The median
follow-up was 38.5 months (range 1–117 months). The regional
committee of Scientific Ethics, Aarhus approved the study, and the
procedures were followed in accordance with the Helsinki
Declaration.
Preparation of total RNA
RNA preparation was performed as described before (Memon
et al, 2004). Briefly, tumour samples were immediately placed in a
denaturing solution (4moll
 1 guanidine thiocyanate, 25mmoll
 1
sodium citrates (PH7), 0.5% sarkosyl and 0.1mmoll
 1 2-
mercaptoethanol) and stored at  801C. A frozen biopsy
(o20mg) was homogenised by a Heidolph Diax 600 mixer. Total
RNA was extracted from tissues according to a slightly modified
method of Chomczynski and Sacchi (1987).
Real-time reverse transcription–polymerase chain
reaction quantification of mRNA
Quantification of mRNA was performed by real-time reverse
transcription–polymerase chain reaction on the Lightcycler
instrument (Roche, Germany) as described before (Memon et al,
2004). Briefly, cDNA was generated in a reverse transcription
reaction, where 1mg RNA was mixed with 2.5 units AMW reverse
transcriptase (Applied Biosytems, Foster city, USA) in a reaction
mixture containing 10mM Tris-HCl (pH 8.3), 1Uml
 1 RNase
inhibitor, 1mmoll
 1 deoxyribonucleoside triphosphate (dATP,
dTTP, dGTP and dCTP), 2.5mmoll
 1 16mer d(T)16 primer,
50mmoll
 1 KCl, 6.25mmoll
 1 MgCl2 in a total volume of 20ml
(all reagents from Applied Biosystem). The reactions were
incubated in a perkin Elmer 9700 thermocycler for 90s at 941C
followed by 30min at 421C and finally at 941C for 1min. Real-time
polymerase chain reaction (PCR) was performed with the Light-
cycler Sybr Green I quantification kit (Roche) in a total volume of
10ml in LC glass capillaries (Roche). The HER1 primers: 50-
AGAGGAGAACTGCCAGAA-30 (sense) and 50-GTAGCATTTATG
GAGAGTG-30 (antisense); HER2 primers: 50-CCAGGACCTGCT
GAACTGGT-30 (sense) and 50-GTACGAGCCGCACATCC-30 (anti-
sense) give rise to a 454 and 272bp PCR product, respectively.
HER3 and HER4 quantifications were previously determined by
same method by amplifying a 365 and 265bp fragment,
respectively (Memon et al, 2004). Beta-actin mRNA was used as
an endogenous RNA control, which has been used as control gene
in various studies on bladder cancer (Vageli et al, 1996; Chiu et al,
2002) as well as on breast cancer (Agudo et al, 2004). Specificity
was verified by the size of the PCR product on agarose gel
electrophoresis and nucleotide sequencing using a 310 genetic
analyser (Applied Biosystems). A calibration curve and positive
and negative controls were included in each run. The results are
presented based on a calibration curve of mRNA. The calibration
curve was composed of serial dilutions of a pool of mRNA isolated
from; HCV cells for measurement of HER1 and HER2 whereas
HEC and KLE cells were used for HER3 and HER4, respectively.
Likewise, actin mRNA was analysed in the same samples employ-
ing mRNA isolated from HCV as calibrator. All the quantifications
in this study are presented as ratio between the target gene and
beta-actin. Quantifications were performed using Lighcycler
Software Version 3 (Roche).
Table 1 Clinical data in 88 bladder cancer patients
Variables No. of patients
Sex
Male 69
Female 19
Age (years)
Median 72
Range 53–88
Stage
Ta 21
T1 18
T2–T4 49
Grade
I/II 26
III/IV 62
Tumour type
Papillary 38
Solid 37
Mixed 13
Tumour size (cm)
o35 0
433 8
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Nonparametric tests were used throughout this study. Two-sided
P-values o0.05 were considered to be significant. The w
2 test was
used to compare the expression of the EGF family members with
clinical stage, grade, tumour type and size of the tumour. Life table
calculations were carried out using the Kaplan–Meier method.
Comparison between the curves was carried out using log-rank
test. (The software Graph Pad Prism (version 4) was used for
statistical analysis.)
RESULTS
Pattern of EGF family receptor expression and correlation
with histopathological parameters of bladder cancer
We report the mRNA expression of HER1 and HER2 in bladder
cancer biopsies from 88 patients followed for a median of 38.5
months (range 1–117 months). HER3 and HER4 mRNA expres-
sions have previously been determined on the same samples
(Memon et al, 2004). HER1 was expressed in 96% (85 out of 88
Table 2 Correlation between combinations of HER1 and HER3/HER4 and clinicopathological parameters of bladder cancer
Receptor combinations
HER1 +   +/ 
a   +
HER3 + + +/ 
a   
HER4 + + +/ 
a   P
b
All tumours 26
c (30.0)
d 15 (17.0) 19 (22.0) 19 (22.0) 9 (10.0)
Stage
Ta–T1 20 (77.0) 10 (67.0) 2 (11.0) 5 (26.0) 0 (0.0) 0.0002
T2–T4 6 (23.0) 5 (33.0) 17 (89.0) 14 (74.0) 9 (100)
Grades
Grade I+II 17 (65.0) 5 (33.0) 2 (11.0) 2 (11.0) 0 (0.0) 0.0018
Grade III+IV 9 (35.0) 10 (67.0) 17 (89.0) 17 (17.0) 9 (100)
Size (cm)
o3 15 (58.0) 10 (67.0) 8 (42.0) 13 (68.0) 4 (44.0) NS
43 11 (42.0) 5 (33.0) 11 (58.0) 6 (32.0) 5(56.0)
Tumour type
Papillary 19 (73.0) 6 (40.0) 6 (32.0) 4 (21.0) 2 (22.0) 0.0042
Solid 3 (12.0) 6 (40.0) 7 (36.0) 14 (74.0) 7 (78.0)
Mixed 4 (15.0) 3 (20.0) 6 (32.0) 1 (5.0) 0 (17.0)
NS¼not significant.
aBoth high and low HER1 tumours expressing either high HER3 or high HER4.
bw
2 test, analysis was performed between combinations of +HER1/+HER3/
+HER4, +HER3/+HER4 and +HER1 only expressing tumours.
cNo. of patients.
dPercentage.
Table 3 Correlation between combinations of HER2 and HER3/HER4 and clinicopathological parameters of bladder cancer
Receptor combinations
HER2 +   +/ 
a   +
HER3 + + +/ 
a   
HER4 + + +/ 
a   P
b
All tumours 29
c (33.0)
d 12 (14.0) 20 (22.0) 23 (26.0) 4 (5.0)
Stage
Ta–T1 23 (79.0) 7 (58.0) 5 (25.0) 4 (17.0) 0 (0.0) 0.0054
T2–T4 6 (21.0) 5 (42.0) 15 (75.0) 19 (83.0) 4 (100)
Grades
Grade I+II 16 (55.0) 6 (50.0) 2 (11.0) 2 (9.0) 0 (0.0) NS
Grade III+IV 13 (45.0) 6 (50.0) 18 (89.0) 21 (91.0) 4 (100)
Size (cm)
o3 21 (72.0) 4 (33.0) 9 (45.0) 14 (61.0) 2 (50.0) NS
43 8 (28.0) 8 (77.0) 11 (55.0) 9 (39.0) 2 (50.0)
Tumour type
Papillary 21 (73.0) 5 (42.0) 6 (30.0) 6 (26.0) 0 (0.0) 0.0017
Solid 3 (10.0) 6 (50.0) 8 (40.0) 16 (70.0) 4 (100)
Mixed 5 (17.0) 1 (8.0) 6 (30.0) 1 (4.0) 0 (0.0)
NS¼not significant.
aBoth high and low HER2 tumours expressing either high HER3 or high HER4.
bw
2 test, analysis was performed between combinations of +HER2/+HER3/
+HER4, +HER3/+HER4 and +HER1 only tumours.
cNo. of patients.
dPercentage.
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samples. As previously reported (Memon et al, 2004), HER3 and
HER4 expressions were found in 99 (87 out of 88 patients) and
63% (56 out of 88 patients) of the tumour samples, respectively.
Median concentrations of each mRNA examined were selected as
the cutoff point, dividing all patients into two groups, one with
high expression (above median, denoted as (þ)) and another with
low expression (at or below median, denoted as ( )). High
expressions of HER1 or HER2 when coexpressed with high HER3
and HER4 strongly correlated (Po0.05) with good prognostic
indicators of bladder cancer (early stage of tumour (Ta–T1), low
grade (Grade I/II) and papillary type of tumour). In contrast,
tumours expressing only high HER1 or HER2 but low HER3 or
HER4 correlated with poor prognostic parameters of bladder
cancer (late stage of tumour (T2–T4), high-grade (Grade III/IV)
and solid type of tumour). In relation to stages of the tumour, 77
and 79% of the patients coexpressing high levels of HER1, HER3
and HER4 (þHER1/þHER3/þHER4) (Table 2) or high levels of
HER2, HER3 and HER4 (þHER2/þHER3/þHER4) (Table 3),
respectively, correlated with early stage of the tumour (Ta–T1).
Whereas, 100% of tumours overexpressing HER1 or HER2 with
low expression of HER3 and HER4 (þHER1/ HER3/ HER4) and
(þHER2/ HER3/ HER4) correlated with late stage (T2–T4) of
the bladder cancer.
Correlation with survival
The median mRNA concentrations of each EGF receptors in all the
bladder tumours were selected as the cutoff limit and patients were
categorized into groups with high (above median) or low
expression (below median). Kaplan–Meier survival curves were
made to evaluate the impact of expression of HER1 and HER2
individually and in combination with HER3 and HER4. Patients
were divided into the following groups. Group (a) patients
expressing high HER1, HER3 and HER4, (b) patients expressing
low HER1 with high HER3 and HER4, (c) patients expressing low
all four receptors and (e) patients expressing high HER1 with low
HER3 and HER4. There was a group of patients expressing high
HER1 together with a high expression of either HER3 or HER4 and
another group of patients expressing low HER1 together with a
high expression of either HER3 or HER4, both groups were
combined and shown as (d). The same grouping was performed for
the HER2, HER3 and HER4 combinations (Figures 1 and 2 present,
legend tables).
Expression of either HER1 or HER2 (Figures 1A and B) or these
two receptors in combination (data not shown) did not correlate
with survival (P40.05). However, patients having tumours
expressing high HER1 together with high expressions of HER3
and HER4 had a better survival (Figure 2A) compared to the
patients expressing high HER1 but low expression of HER3 and
HER4 (P¼0.0006) (Figure 2A, compare a with e). Also patients
having tumours expressing high HER2 together with high
expressions of HER3 and HER4 had a better survival (Figure 2B)
than did the patients expressing high HER2 but low HER3 and
HER4 (P¼0.0005) (Figure 2B, compare a with e). It was also
observed that the presence of high expression of either HER1 or
HER2 did not affect the survival of high HER3- and HER4-
expressing tumours (P40.05). Patients with high HER3 and HER4
expression irrespective of the presence of high or low HER1
(Figure 2A, compare a and b) or HER2 (Figure 2B, compare a and
b) showed comparable and favourable survival.
We also analysed the effect of high expression of HER3
(irrespective of the expression of HER4) together with high
expression of HER1 or HER2. Likewise, the effect of high HER4
(irrespective of the HER3 expression) in combination with high
expression of HER1 or HER2 was analysed. Our results showed
that high expression of HER3 together with high HER1 or HER2
expression also correlated to better survival (data not shown).
Similarly, high expression of HER4 together with high HER1 or
HER2 expression also correlated to better survival (data not
shown). However, the effect was less marked than observed for
tumours where both HER3 and HER4 were coexpressed at a high
level together with HER1 or HER2.
We also analysed the relation between survival and HER3 and
HER4 expressions in the subgroup of patients with invasive
tumours (T1–T4). Our results show that expression of high HER3
and HER4 compared to low HER3 and HER4 correlated with better
prognosis even in this highly invasive group of tumours
(Figure 3A). In addition, we also analysed the survival function
of HER3 and HER4 in the group of patients with solid and mixed
type of tumours. In this group, we also found a trend showing that
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Figure 1 Kaplan–Meier overall survival analysis comparing patients with
high (above median) and low (below median) HER1 (A) or HER2 (B)
individual expression in 88 bladder cancer patients. P-value represents log-
rank differences in survival between two groups.
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compared to the patients expressing low HER3 and HER4
(Figure 3B).
Finally, we examined whether treatment of patients before
biopsies were taken, had any effect on our final conclusions, but
we did not find this to be the case (data not shown).
DISCUSSION
The EGF family receptors and its ligands are involved in cancer
development and prognosis. Abnormal function of the members of
the EGF family has been linked to bladder cancer prognosis.
Several reports, based mainly on the expression of HER1 and
HER2, demonstrate that the EGF family of receptors are involved
in poor prognosis in various cancers including bladder cancer
(Lonn et al, 1995; Arpino et al, 2004; Blackwell et al, 2004; Popov
et al, 2004). In contrast to HER1 and HER2, our study on bladder
tumours (Memon et al, 2004) and other studies on breast tumours
(Abd El-Rehim et al, 2004) have suggested that increased
expression of HER3 and HER4 is associated with improved
survival. This is supported by data on cancer cells that
demonstrate a ligand-dependent proapoptotic function of the
HER4-expressing cells (Sartor et al, 2001). Furthermore, recent
findings about HER4 expression in breast tumours also point
towards a proapoptotic function of HER4 (Barnes et al, 2005).
These studies demonstrate that different EGF receptors function
differently, and that the expression pattern of the individual
receptors may be of importance in determining the cellular
outcome. However, very limited information is available where the
expression of all four receptors has been analysed and related to
the survival of bladder cancer patients.
Our results show that neither individual nor combined
expression of HER1 and HER2 correlated with survival, in
agreement with some of the previous reports on bladder cancer
(Jimenez et al, 2001; Thogersen et al, 2001). However, conflicting
reports have been published on the prognostic value of HER1 and
HER2 receptors in bladder cancer. For example, HER1 and HER2
expressions were correlated with both good (Gandour-Edwards
et al, 2002; Chakravarti et al, 2005) and poor (Kruger et al, 2002;
Popov et al, 2004) prognosis in bladder cancer, whereas other
suggest that there is either no or only limited prognostic
significance of HER1 and HER2 expression in this disease (Mellon
et al, 1996; Ravery et al, 1997).
In vitro studies suggest that cell lines expressing only one of the
HER receptors were unable to form tumours in animals with the
exception of HER1, which was weakly tumorigenic. Moreover,
although unable to form tumours when expressed alone, HER2 was
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Figure 2 Kaplan–Meier survival curves demonstrating survival function of all EGF receptors in various combinations in 88 bladder cancer patients. HER1
(A) or HER2 (B) expressing tumours correlated to worst prognosis in the absence of both HER3 and HER4 expressions. Legend tables showing various
combinations analysed. P-value represents log-rank difference in survival between all groups.
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Of all combinations analysed, cells expressing both HER1 and
HER2 were the most aggressive (Cohen et al, 1996). In addition,
when HER2-expressing cells were transfected with HER4, anti-
proliferative and differentiation responses were observed (Sartor
et al, 2001), suggesting that HER4 signalling has an opposite effect
than HER2 signalling.
Based on these observations, we hypothesised that the final
outcome of the bladder cancer patients may depend on the balance
between the expressions of EGF receptors.
We demonstrate that a high expression of either HER1 or HER2
has no effect on survival when HER3 and HER4 are present. In
contrast, high expressions of either HER1 or HER2, in tumours
where HER3 and HER4 are low, result in significantly reduced
survival. In our group of patients, we observed that 12 patients
were expressing high concentrations of HER1 or HER2 with low
HER3 and HER4, and 10 of these patients died during the course of
follow-up (8 months median follow-up). In contrary, 34 patients
expressing high HER1 or HER2 together with high HER3 and
HER4 correlated with longer survival (44 months median follow-
up), and only 10 out of 34 patients died during the follow-up
period. This suggests that expression of HER1 and HER2 is
involved in tumour progression and poor prognosis in the bladder
tumours only when HER3 and HER4 are low. In keeping with our
results, studies on breast cancer investigating the expression of the
individual EGF receptors also show that increased HER3 and HER4
expression appears to be associated with better prognosis (Quinn
et al, 1994; Knowlden et al, 1998). However, it should be noted that
in another study, only HER4 was found to be associated with a
better prognosis whereas HER1, HER2 and HER3 overexpression
was associated with a poor outcome (Witton et al, 2003).
In this study, we are able to show that HER3 and HER4
expression can influence the effect of HER1 and HER2 on survival.
These data emphasise that combined analysis of the expression of
all four EGF receptors provide more accurate information on the
tumour behaviour than analysis of the expression of the individual
receptors. Therefore, one possibility for the conflicting data on the
consequences of high HER1 and HER2 expression in bladder
cancer patients published until now could be related to the
function of HER3 or HER4 expression, which was ignored in most
of the studies.
In conclusion, our results suggest that expression of different
combinations of receptor can change the final outcome of the
disease, and we suggest that the expression of HER3 and HER4
should be taken into account for future evaluation of the
consequences of HER1 and HER2 expression in bladder cancer.
This might also be of importance in identifying patients, which
may benefit from the specific antitumoural drugs designed to
target the EGF receptors.
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